Alcon acquires Neurotech for $550 million
Bitget2026/10/20 20:36- Alcon acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO.
- Additional contingent payments may be required, including upon achievement of commercial milestones.
- ENCELTO is the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a progressive retinal disease.
- The therapy received FDA approval in March 2025 and is available only in the U.S.
- The transaction is expected to modestly boost net sales growth, slightly dilute core diluted EPS in 2027 and be accretive thereafter.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI trading weakens, funds return to safe-haven assets, and U.S. Treasury yields hit their lowest level in nearly a month
The outlook for AI trading is being reassessed, reshaping global asset allocation. Stock market pressure is prompting investors to flock to safe-haven assets such as US Treasuries, yen, and Swiss franc. The 30-year US Treasury yield hit 5.38%, the lowest level since September 23. The yen appreciated 0.3% against the US dollar to 157.68, and the Swiss franc rose 0.2%. Safe-haven buying emerged as oil prices surged due to an attack in Saudi Arabia. The future direction will depend on which theme dominates: inflationary pressures or a cooling in AI trading.
AI sell-off suppresses risk appetite, copper prices follow downward
The sell-off in tech stocks has dampened risk appetite, leading to a decline in copper prices.
Japanese Yen: Range trading with upside medium term risk against US Dollar – UOB
Skonec Entertainment Faces Shareholder Register Access Lawsuit in Control Dispute
Crypto prices
More
